The Evolution of Oral-Systemic Defense
Understanding our manufacturing philosophy begins with understanding the evolution of the global P. gingivalis threat.
The Local Threat
Global dental associations classify P. gingivalis as the primary keystone pathogen responsible for severe localized periodontitis and tooth loss.
The Botanical Breakthrough
The Journal of Agricultural and Food Chemistry publishes the landmark study proving that specific Magnolia Bark Extracts can destroy over 99.9% of oral bacteria within 5 minutes.
The Neurological Crisis
A massive US study in Science Advances shocks the medical world by discovering the pathogen infiltrating the brains of Alzheimer's patients.
Cellular Mutation Link
Breakthrough clinical data from Wuhan University demonstrates the bacteria releases vesicles that actively drive cancer metastasis.
The Active Clinical Frontline
Major US clinical trials continue aggressively targeting P. gingivalis to neutralize its ability to cross the blood-brain barrier, confirming it as a permanent, ongoing focus of modern systemic medicine.
The MBK Solution
Using the 2007 botanical baseline combined with 2026 bio-fermented peptides and live enzymes, MBK Clinical engineers the P21 Systemic Defense Series.
The MBK Private Label Pipeline
Partnering with MBK Clinical grants your brand access to proprietary bio-enzymatic matrices and premium clinical-grade cosmetic manufacturing. Our onboarding pipeline is engineered for absolute formula security and rapid global market deployment.
Formula Selection & NDA
We consult with your team to select the appropriate MBK Systemic Matrix. To protect both your brand's market strategy and our proprietary manufacturing technology, a standard mutual Non-Disclosure Agreement (NDA) is established prior to initiating the physical prototyping phase.
R&D Prototyping (Sampling)
Our laboratory engineers your custom physical prototypes, calibrating the specific flavor profiles and active ingredient thresholds for your target demographic.
Packaging & Compliance Architecture
While prototypes are in transit, our compliance team works with your brand to ensure your chosen packaging maintains the necessary pH and stability for our active enzymes.
Mass Production & Cold-Process Manufacturing
Your formula enters our advanced clean-room facilities. We utilize specialized cold-process manufacturing to ensure temperature-sensitive actives remain fully stabilized.
R&D Initiation & Clinical Prototyping
"Because MBK Clinical utilizes highly sensitive, premium active ingredients such as bio-fermented peptides and live oxygenating enzymes we do not pull standard 'stock' samples from a warehouse. Every requested sample is a live, calibrated prototype engineered specifically for your brand's evaluation."
- The R&D Deposit: To initiate the laboratory prototyping process, we require a standard Clinical Prototyping Deposit (typically ranging from $200 to $500 USD, depending on the complexity of the requested formulation). This fee filters out non-serious inquiries and covers our specialized laboratory engineering time.
- The Manufacturing Credit: We view this deposit as the beginning of a true manufacturing partnership. Therefore, 100% of your R&D Prototyping Deposit will be completely credited and deducted from the invoice of your first mass-production MOQ order.
- What is Included: Your deposit covers the laboratory engineering time, premium raw materials, international express courier shipping, and direct access to our Chief Chemists to refine the sensory profile.
Your R&D Prototyping Deposit is an investment in our long-term partnership. When you proceed with your first mass-production order, the entire deposit amount will be directly subtracted from your final bulk invoice.
Secure checkout powered by global banking protocols.